RGLS Logo

Regulus Therapeutics Inc. (RGLS) 

NASDAQ
Market Cap
$92.36M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
312 of 774
Rank in Industry
183 of 432

Largest Insider Buys in Sector

RGLS Stock Price History Chart

RGLS Stock Performance

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a …

Insider Activity of Regulus Therapeutics Inc.

Over the last 12 months, insiders at Regulus Therapeutics Inc. have bought $7,280 and sold $30,379 worth of Regulus Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Regulus Therapeutics Inc. have bought $9.14M and sold $22,684 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Collier Kathryn J (director) — $7,280.

The last purchase of 4,000 shares for transaction amount of $7,280 was made by Collier Kathryn J (director) on 2024‑07‑25.

List of Insider Buy and Sell Transactions, Regulus Therapeutics Inc.

2024-07-25Purchasedirector
4,000
0.0063%
$1.82$7,280-10.80%
2024-01-18SaleChief Executive Officer
14,580
0.0687%
$1.19$17,359+33.20%
2024-01-18SaleSr. VP & General Counsel
5,468
0.0258%
$1.19$6,510+33.20%
2024-01-18SaleChief Financial Officer
5,468
0.0258%
$1.19$6,510+33.20%
2022-03-01PurchaseChief Scientific Officer
76,686
0.0537%
$0.23$17,638-25.22%
2022-02-04PurchaseChief Scientific Officer
23,314
0.0156%
$0.23$5,362-25.63%
2022-01-26PurchasePresident and CEO
100,000
0.0685%
$0.22$21,520-15.91%
2021-05-17SalePresident and CEO
4,186
0.0053%
$0.89$3,726-53.85%
2021-05-17SaleSr. VP & General Counsel
860
0.0011%
$0.89$765-53.85%
2021-02-16SalePresident and CEO
4,144
0.0052%
$1.72$7,128-62.37%
2021-02-16SaleSr. VP & General Counsel
828
0.001%
$1.72$1,424-62.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%
2020-12-04Purchase10 percent owner
4.4M
7.578%
$0.62$2.74M+22.37%

Insider Historical Profitability

<0.0001%
Hagan Joseph PChief Executive Officer
57112
0.0872%
$1.41414<0.0001%
Collier Kathryn Jdirector
6740
0.0103%
$1.4120<0.0001%
CROOKE STANLEY T
7049500
10.7626%
$1.4110
PARSHALL B LYNNE
7049500
10.7626%
$1.4110
MAKOWER JOSHUA10 percent owner
6451056
9.8489%
$1.4120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Federated Hermes$34.43M19.6312.85M+231.63%+$24.05M0.08
Nea Management Company Llc$18.63M9.886.47M+232.44%+$13.02M0.09
RA Capital Management, L.P.$18M9.556.25MNew+$18M0.02
Vivo Capital$14.4M7.645MNew+$14.4M1.25
Adage Capital Partners Gp L L C$10.6M5.623.68MNew+$10.6M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.